Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in...

|By:, SA News Editor

Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in 18%-28% of patients, is at the forefront of treatments designed to enable the body's immune-system to kill cancer cells. Other firms in this "revolution in the making" include Merck (MRK), Roche (RHHBY.PK), Teva (TEVA) and GSK (GSK).